Cancer Drug Design and Discovery

Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.

Provides a clinical perspective on the development of new molecularly targeted anticancer agents with the latest and most promising chemotherapeutic approachesOffers a broad view of where the field is going, what tools drug discovery is using to produce new agents and how they are evaluated in the laboratory and clinicFeatures 6 new chapters devoted to advances in technology and successful anticancer therapies, such as cancer genomics and personalized medicine, DNA-targeted agents, B-Raf inhibitors and moreEach chapter includes extensive references to the primary and review literature, as well as to relevant web-based sources

Introduction - Stephen Neidle

Foreword - Hilary Calvert

Part I. Basic Principles and methodology

Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman and Ian Collins

Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo and Federico Innocenti

Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti

Part II. Drugs in the laboratory and clinic

Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens

Temozolomide: patents and the perils of invention — Malcolm Stevens

A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly

Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali

The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and Rolf W. Hartmann

Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik

Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents — Ian R Hardcastle

Targeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee

Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W. Rewcastle

Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley

Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan

Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris

Part III. The reality of cancer drugs in the clinic

Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren and Christopher. A. Slapak

Anticancer drug registration and regulation: current challenges and possible solutions — David Taylor, Erling Donnelly and Silvia Chioato